Hyderabad: Dr Reddy's Labs said Wednesday that Health Canada has approved its generic semaglutide injection, making it the first company to secure mar.

Indian equity markets opened weak on Friday amid persistent geopolitical tensions and the ongoing Q4 earnings season. Sensex fell 400 points to 77,263, while Nifty declined 100 points in early trade. IT, financial, and pharma stocks faced heavy selling pressure, with Cipla, Infosys, Dr Reddy’s, Sun Pharma, TCS, and ICICI Bank as top laggards. FMCG and chemical stocks provided some support.

In this briefing: Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums Primer: Anthem Biosciences (1234D IN) - Apr 2026 Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins 1. Sharda Cropchem - Continuing Momentum Despite Geopolitical Tantrums Sharda Cropchem is an asset-light agrochemical supplier that sources products mainly from China and India, sells globally, and builds competitive advantage through extensive regulatory product registrations instead of manufacturing capabilities. They invest heavily in product registrations, creating large pipeline that converts into revenue over time, driving strong cash flows funding growth internally, and supporting dividends despite high accounting amortization charges. Sharda’s massive registration pipeline and presence in regulated markets drive growth despite sourcing and forex risks.

In this briefing: Primer: Anthem Biosciences (1234D IN) - Apr 2026 Amagi Media Labs: Taking Media Companies to the Cloud Universe Charting Course: Oil Cognitive Arbitrage and the PetroYuan Debut (4/17/26) Paracetamol’s Supply Crisis: The Tablet Squeezing Indian Pharma Margins Gold Loan: How a Collateral-First Product Became India's Largest Retail Loan 1. Primer: Anthem Biosciences (1234D IN) - Apr 2026 Anthem Biosciences is a fully integrated Contract Research, Development, and Manufacturing Organization (CRDMO) providing end-to-end services for small and large molecules to the global pharmaceutical and biotechnology sectors. The company has demonstrated a strong financial track record, with a 32% CAGR in operating revenue between FY23 and FY25, and boasts industry-leading EBITDA margins. Key growth drivers include its leadership in fermentation capacity in India, expertise in advanced therapeutic modalities like ADCs and RNAi, and a strategic focus on backward integration to reduce reliance on external suppliers.

Hindustan Unilever and Colgate Palmolive (India) are among the companies expected to report their Q2 results on Thursday

The new U.S. duty has already triggered a slide in major Asian pharma names, raising concerns about how Indian peers will react in the coming weeks.

The analyst noted that Syngene, Piramal Pharma, and Zydus Lifesciences may be better positioned, as their contract manufacturing models and biologics portfolios are less susceptible to the tariff impact.

Urban Company is set to list at 10 am, GMP data indicating nearly a 50% premium over the issue price.

Gift Nifty indicates a positive opening for benchmark Indian indices